Company intelligence / Profile preview
Tinkeso Therapeutics
Valhalla, New York, United Statestinkeso.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Tinkeso Therapeutics is developing novel off-the-shelf, allogeneic iNKT cell therapies for cancer and immune-mediated disorders. Their lead program targets leukemia and leverages proprietary engineering technologies. No clinical results have been reported as of early 2025; programs are in discovery/preclinical stages.[1][4]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic invariant Natural Killer T (iNKT) cell therapiesEngineered NKT cell therapiesCAR-T-like approaches (using nonviral Sleeping Beauty transposon system)[3][5]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Tinkeso Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tinkeso Therapeutics.